Moderna (MRNA) Stock: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$143.97
7.35 (5.38%)
â˛
5d:
-3.29%
30d:
+126.12%
90d:
+190.03%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 1, 2026 at $148.71 · last confirmed Sep 11, 2026
Strength: 7.0/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MRNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MRNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $143.97, which is considered slightly high relative to its 30-day fair value range of $67.30 to $153.20.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $130.38, while resistance sits at $156.42. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: MRNA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $116.50. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $130.38, while resistance sits at $156.42. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: MRNA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $116.50. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$67.30 -
$153.20
Company Quality Score
39/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
31.6%
Protect Your Profits
Holding MRNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: Strong upward momentum (+5.4%)
- BEARISH: Trading 19.1% above Wall St target ($116.50)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$67.30 -
$153.20
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$130.38
Resistance Level
$156.42
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.23
Wall Street Target
$116.50
(-19.1%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
-85.1%
Profit Margin
-141.4%
Share & Embed Analysis
Last updated: September 12, 2026 3:55 AM ET
Data refreshes hourly during market hours. Next update: 4:55 AM
Data refreshes hourly during market hours. Next update: 4:55 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
